10-Year outcome for men with localized prostate cancer treated with external radiation therapy: Results of a cohort study

Journal of Urology

Volumn 171, Issue 1, 2004, Pages 210-214

  Zietman, A L ^a   Chung, C S ^a   Coen, J J ^a   Shipley, W U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Outcome assessment (healthcare); Prostatic neoplasms; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION BEAM; RADIATION DOSE; RECURRENT CANCER; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0346848829     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000100980.13364.a6     Document Type: Article

References (17)

1. Gretzer, M. B., Trock, B. J., Han, M. and Walsh, P. C.: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol, 168: 1419, 2000
2. Amling, C. L., Bergstralh, E. J., Blute, M. L., Slezak, J. M. and Zinke, H.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol, 165: 1146, 2001
3. Connell, P. P., Ignacio, L., McBride, R. B., Weichselbaum, R. R. and Vijayakumar, S.: Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. Urology, 54: 875, 1999
4. Shipley, W. U., Thames, H. D., Sandler, H. M., Hanks, G. E., Zietman, A. L., Perez, C. A. et al: Radiation therapy for clinically localized prostate cancer, a multi-institutional pooled analysis. JAMA, 281: 1598, 1999
5. Hanks, G. E., Hanlon, A. L., Schultheiss, T. E., Pinover, W. H., Movsas, B., Epstein, B. E. et al: Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys, 41: 501, 1998
6. Zelefsky, M. J., Fuks, Z., Hunt, M., Lee, H. J., Lombardi, D., Ling, C. C. et al: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol, 166: 876, 2001
7. Consensus statement: guidelines for PSA following radiation therapy. Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys, 37: 1035, 1997
8. Glatstein, E. and Makuch, R. W.: Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol, 2: 488, 1984
9. Vicini, F. A., Kestin, L. L. and Martinez, A. A.: The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys, 45: 553, 1999
10. D'Amico, A. V., Chen, M. H., Oh-Ung, J., Renshaw, A. A., Cote, K., Loffredo, M. et al: Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys, 54: 436, 2002
11. Zietman, A., Moughan, J., Owen, J. and Hanks, G.: The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. Int J Radiat Oncol Biol Phys, 50: 75, 2001
12. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 447, 1958
13. Mantel, N. and Haenszel, W.: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22: 719, 1959
14. Zietman, A. L.: Dose escalation in localized prostate cancer: make no assumptions. Int J Radiat Oncol Biol Phys, 54: 635, 2002
15. Zietman, A. L., Zehr, E. M. and Shipley, W. U.: The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. Int J Radiat Oncol Biol Phys, 43: 715, 1999
16. Critz, F. A., Williams, W. H., Holladay, C. T., Levinson, A. K., Benton, J. B., Holladay, D. A. et al: Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology, 54: 968, 1999
17. Pollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., von Eschenbach, A. C., Antolak, J. A. et al: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol, 18: 3904, 2000